GUELPH, ON, June 9, 2023 /PRNewswire/ - Biorem Inc. (TSXV: BRM) ("Biorem", or "the Company") announces that, pursuant to its incentive Stock Option Plan, it has granted incentive stock options to certain directors, of the Company to purchase up to an aggregate of 50,000 common shares in the capital stock of the Company. The options are exercisable at a price of $1.01 per share for a period of ten years from the date of grant.
About BIOREM Inc.
BIOREM is a leading clean technology company that designs, manufactures and distributes a comprehensive line of high-efficiency air emissions control systems used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). With sales and manufacturing offices across the continent, a worldwide sales representative network and more than 1,800 installed systems worldwide, BIOREM offers state-of-the-art technology-based products and peace of mind for municipalities, industrial companies and their surrounding communities. Additional information on Biorem is available on our website at www.biorem.biz.
The automotive stereo camera market size is estimated to grow by USD 534.29 million from 2022 to 2027, growing at a CAGR of 8.75%. The automotive stereo camera market is fragmented owing to the presence of many global and regional companies. A few...
The "Border Security Systems - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Border Security System Market to Reach $70.5 Billion by 2030The global market for Border Security System estimated...
The "Global Peptone Market Report and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
Global peptone market is forecasted to reach a value of $210 million by 2028 from $166.12 million in 2023, growing at a CAGR of...
The U.S. Food and Drug Administration (FDA) has granted approval for EntroGen's CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix® (panitumumab), a targeted therapy used in the treatment of colorectal cancer. This landmark...
The radiopharmaceuticals market size is expected to grow by USD 4.61 billion from 2022 to 2027. In addition, the momentum of the market will be progressing at a CAGR of 10.22% during the forecast period, according to Technavio Research. The market...
Renesas Electronics Corporation (TSE:6723, "Renesas"), a premier supplier of advanced semiconductor solutions, today announced a strategic partnership with EdgeCortix, a leading provider of energy efficient, Artificial Intelligence (AI) processing...
